According to recent research, a widely accessible and often used medication may be able to effectively manage irritable bowel syndrome (IBS) symptoms in individuals seen in general practitioners’ offices.
The results of the ATLANTIS trial were used in the study, which was presented at UEG Week 2023, a meeting organized by the European Society of Gastrointestinal Endoscopy, and showed that amitriptyline reduces symptoms of IBS. Currently, a variety of medical conditions are treated with the medication in little dosages.
Approximately one in twenty individuals worldwide suffer with irritable bowel syndrome, which results in altered bowel movements and pain in the abdomen. There is presently no treatment for the illness, which varies in severity over time. When symptoms flare up, IBS can significantly lower a person’s quality of life by interfering with their ability to work and socialize.
The National Institute for Health and Care Research (NIHR) provided funding for the study, which was conducted by scientists from the Universities of Leeds, Southampton, and Bristol. Using an adjustment document created specifically for the trial, general practitioners (GPs) prescribed the drop to IBS patients who controlled their own dosage according on the severity of their symptoms. This research was carried out in primary care.
Two randomly selected groups of participants were given amitriptyline in one group and a placebo in the other. Using a patient dose adjustment document that was created specifically for this trial in collaboration with patient representatives, those who were administered the medications managed how many pills they consumed during the experiment. It implied that individuals might adjust their dosage in accordance with their symptoms or any side effects they encountered.
The results, according to the sources, demonstrated that amitriptyline users were nearly twice as likely to report an overall improvement in their symptoms as those who took a placebo.
Read More: https://insightscare.com/